Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Santiago Pardo

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Multiple Sclerosis and Related Disorders|March 3, 2019
Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorderSara Salama, Santiago Pardo, Michael Levy
Expert Opinion on Investigational Drugs|February 22, 2018
Investigational drugs in development to prevent neuromyelitis optica relapsesFriedemann Paul, Olwen Murphy, Santiago Pardo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 26, 2019
MOG antibody-associated encephalomyelitis/encephalitisSara Salama, Majid Khan, Santiago Pardo, et al.
Research in Developmental Disabilities|February 21, 2025
Assessing childhood impact: Virtual and in-person counseling for children's language development challengesAlba Ayuso-Lanchares, Inés Ruiz-Requies, Rosa Belén Santiago-Pardo
Multiple Sclerosis and Related Disorders|July 21, 2019
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorderSantiago Pardo, Gavin Giovannoni, Christopher Hawkes, et al.
Multiple Sclerosis and Related Disorders|July 27, 2018
MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorderRam Narayan, Alexandra Simpson, Katelyn Fritsche, et al.
Multiple Sclerosis and Related Disorders|March 5, 2022
A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis opticaDylan R Rice, Shuhei Nishiyama, Santiago Pardo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2019
Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinningElias S Sotirchos, Angeliki Filippatou, Kathryn C Fitzgerald, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
BMC Infectious Diseases|June 17, 2021
Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2Bianca A Trombetta, Savannah E Kandigian, Robert R Kitchen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|March 3, 2019
Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorderSara Salama, Santiago Pardo, Michael Levy
Expert Opinion on Investigational Drugs|February 22, 2018
Investigational drugs in development to prevent neuromyelitis optica relapsesFriedemann Paul, Olwen Murphy, Santiago Pardo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 26, 2019
MOG antibody-associated encephalomyelitis/encephalitisSara Salama, Majid Khan, Santiago Pardo, et al.
Research in Developmental Disabilities|February 21, 2025
Assessing childhood impact: Virtual and in-person counseling for children's language development challengesAlba Ayuso-Lanchares, Inés Ruiz-Requies, Rosa Belén Santiago-Pardo
Multiple Sclerosis and Related Disorders|July 21, 2019
Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorderSantiago Pardo, Gavin Giovannoni, Christopher Hawkes, et al.
Multiple Sclerosis and Related Disorders|July 27, 2018
MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorderRam Narayan, Alexandra Simpson, Katelyn Fritsche, et al.
Multiple Sclerosis and Related Disorders|March 5, 2022
A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis opticaDylan R Rice, Shuhei Nishiyama, Santiago Pardo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2019
Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinningElias S Sotirchos, Angeliki Filippatou, Kathryn C Fitzgerald, et al.
Multiple Sclerosis and Related Disorders|July 7, 2020
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patientsDaniel H Whittam, Alvaro Cobo-Calvo, A Sebastian Lopez-Chiriboga, et al.
BMC Infectious Diseases|June 17, 2021
Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2Bianca A Trombetta, Savannah E Kandigian, Robert R Kitchen, et al.
Pageof 2